License to Kill Tumors: How Much Hope is Justified for Trail

Authors: Frank, S.; Ebert, A.D.

Source: Current Pharmaceutical Design, Volume 7, Number 16, 1 November 2001 , pp. 1689-1701(13)

Publisher: Bentham Science Publishers

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

In 1995, a new cytokine termed TRAIL (tumor necrosis factor - related apoptosis-inducing ligand) was discovered and demonstrated to selectively induce programmed cell death in transformed cell lines. Preclinical cytotoxicity studies in mice and nonhuman primates have produced promising results by demonstrating that TRAIL exerts potent tumoricidal activity but lacks severe toxicity towards normal tissues making it a potentially ideal candidate for cancer therapy. This article reviews aspects of our current understanding of TRAIL signaling pathways and summarizes how this knowledge is currently being translated into TRAIL-based tumor-selective therapeutic strategies

Keywords: Tumors; TRAIL (tumor necrosis factor; Tumor Necrosis Factor; Apoptosis; Fas-associated death domain; FADD converting enzyme; Interferon; Interleukin; C-Jun N-terminal kinase; Nuclear factor kappa B

Document Type: Review article

DOI: 10.2174/1381612013397212

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy